About this trial
This study looks at how well two medicines, brentuximab vedotin and bendamustine, work together for patients with follicular lymphoma that has returned or has not responded to previous treatments. Brentuximab vedotin targets specific cancer cells and delivers a harmful agent to help kill them. Bendamustine is a chemotherapy drug that helps stop cancer cells from growing. The goal is to see how safe and effective this combination is for patients.
The trial's ID number is NCT04587687. This is a Phase 2 trial, which means it is looking at how well the treatment works and its safety. It is regulated by the FDA, and around 23 people are expected to join.
Who can join
This trial is open to adults aged 18 and older, including both men and women. Participants must have a confirmed diagnosis of relapsed or refractory CD30-positive follicular lymphoma. They should be well enough to take part and have a life expectancy of more than three months. The trial team will confirm who can join based on specific health criteria.
Conditions
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the trial will receive both brentuximab vedotin and bendamustine. They will get brentuximab vedotin through an IV over 30 minutes on the first day of treatment. Bendamustine will be given through an IV over 60 minutes on the first two days. This treatment will repeat every 21 days for a total of six cycles, unless there are issues with the treatment. If patients respond well and do not have too many side effects, they may continue on brentuximab vedotin for up to ten cycles.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
University of California Davis Comprehensive Cancer Center
Sacramento, California